Top Telmisartan Brands for Optimal Health Benefits

Telmisartan is a widely prescribed medication for managing high blood pressure, and its efficacy can be attributed to the quality of the brand one chooses. With numerous pharmaceutical companies manufacturing Telmisartan, selecting the best brand is crucial for effective treatment. Factors such as bioavailability, storage stability, and cost can influence a patient's preference and satisfaction with the medication. Explore the list below to discover some of the most reputable brands that healthcare providers often recommend for Telmisartan.

Illustration of telmisartan

Best brands of telmisartan in 2025

Micardis

Micardis, a brand of telmisartan, is a leading product in the angiotensin II receptor antagonist market, widely used to treat hypertension and prevent cardiovascular complications. Distributed by Boehringer Ingelheim Pharmaceuticals, Micardis has been evaluated for safety in over 3700 patients and is available in 20 mg, 40 mg, and 80 mg tablets. The global telmisartan market, which includes Micardis, is expected to reach USD 4.661 billion by 2032, growing at a CAGR of 3.4% during the forecast period. North America, driven by the U.S. market, is anticipated to be the highest shareholder, while the Asia Pacific region is expected to grow at a higher CAGR of 5.5%. The rise in generic telmisartan approvals, such as Mylan Inc.'s ANDA approval in 2014, further fuels market growth. You can find more information about Micardis on their dedicated drug information page.

Telma

Telmisartan, often marketed under the brand name Micardis or Pritor, is a highly effective medication for treating hypertension and reducing the risk of cardiovascular events. The global telmisartan market, which includes brands like Micardis, is expected to reach USD 5.41 billion by 2031, growing at a CAGR of 3.7% from 2024 to 2031. North America, dominated by leading pharmaceutical companies, holds an estimated market share of 40.2% in 2024, while the Asia Pacific region is the fastest-growing market with a CAGR of 5.5% during the forecast period. The rise in healthcare expenditures and increasing awareness of hypertensive therapies in densely populated countries like China and India are key drivers of this market growth. India, France, and China are among the top exporters of telmisartan, with India leading in export shipments. For more details, visit Medical News Today.

Cipla

Cipla Inc is a prominent player in the global telmisartan market, known for its high-quality formulations and extensive distribution networks. The company contributes significantly to the market growth, particularly in the Asia-Pacific region, where countries like India and China are experiencing a surge in hypertension prevalence. Cipla's involvement in the telmisartan market is part of its broader strategy to increase healthcare access and reduce the cost of medications. The Asia-Pacific region, driven by countries like India, is expected to grow at a CAGR of 5.5% during the forecast period, with Cipla being one of the key drivers of this growth. For more details on Cipla's initiatives, explore their official website.

Lupin

Lupin Limited is a prominent player in the telmisartan market, known for its significant presence and contribution to the pharmaceutical industry. As of the financial year 2020, Lupin had a coverage of over 76% in the Indian pharmaceutical market, indicating its strong market presence. The company is involved in various clinical trials and drug developments, including those related to hypertension and cardiovascular conditions. Lupin's involvement in producing telmisartan, an angiotensin II receptor blocker, is crucial given the drug's widespread use in treating hypertension and cardiovascular risk reduction. The company's extensive reach and robust R&D sector contribute to its reputation as one of the best producers of telmisartan. For further insights, explore the Telmisartan Market Research.

Glenmark

Glenmark Pharmaceuticals is a prominent player in the global telmisartan market, known for its high-quality production of this angiotensin II receptor blocker (ARB). As of 2023, Glenmark is one of the key companies profiled in market analyses, alongside other major pharmaceutical firms like C.H. Boehringer Sohn AG & Ko. KG and Torrent Pharmaceuticals Ltd.. The global telmisartan market, valued at USD 4.20 billion in 2024, is expected to grow at a CAGR of 3.7% until 2031, driven by increasing demand for effective hypertension treatments. Glenmark's involvement in this market highlights its commitment to providing affordable and effective healthcare solutions, as generic drug manufacturers now fulfill around 60% of global telmisartan consumption. For more information, visit Glenmark Pharmaceuticals on Wikipedia.

Torrent Pharmaceuticals

Torrent Pharmaceuticals is a leading player in the global telmisartan market, known for its high-quality formulations and extensive distribution network. The company's telmisartan products, such as Telday, are widely prescribed for the treatment of hypertension and cardiovascular conditions, with a significant market share driven by their effectiveness and affordability. In 2024, North America, where Torrent Pharmaceuticals has a strong presence, dominates the global telmisartan market with an estimated 40.2% market share. The Asia Pacific region, particularly countries like India and China, also contributes significantly to the growth of Torrent's telmisartan market due to rising healthcare spending and increasing demand for generics. As of 2020, generic drug manufacturers, including Torrent Pharmaceuticals, fulfilled around 60% of the global consumption of telmisartan, highlighting the shift towards more affordable healthcare options. For more information on their cardiovascular product offerings, download the Torrent Pharmaceuticals cardiovascular product guide.

Ajanta Pharma

Ajanta Pharma is a leading producer of telmisartan, showcasing robust growth in the pharmaceutical industry. The company has delivered better-than-industry growth, with its domestic formulations segment growing 15% YoY in 9MFY23, outpacing the overall Indian Pharmaceutical Market (IPM) growth of 7% YoY. Ajanta Pharma has strengthened its presence in Asia and Africa, with a 45% increase in sales in Africa during Q1 FY2025. The company's focus on new launches, enhanced MR productivity, and penetration into newer geographies has driven its success. With a strong branded generics business contributing 48% of FY22 revenue, Ajanta Pharma is well-positioned in the telmisartan market. For more information, visit their official website.

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories is a leading producer of telmisartan, demonstrating strong market performance with a significant presence in the global generics segment. In FY24, the company reported a 13% year-over-year growth in global generics revenues, driven by increased volumes and new product launches, including several in the U.S. market. Dr. Reddy's has outperformed the India Pharma market over the past four years, with robust growth in various therapies, including cardiology, where telmisartan is a key product. The company's enhanced efforts in regulatory compliance and sustained momentum in launches have further bolstered its growth trajectory. With 21 new product launches in FY24, Dr. Reddy's continues to strengthen its position in the pharmaceutical industry.

Wockhardt

Wockhardt, a prominent pharmaceutical company, is recognized for its high-quality generics, including telmisartan, which is used to treat hypertension and reduce cardiovascular risk. The company's telmisartan tablets are available in various strengths, such as 20 mg, 40 mg, and 80 mg, and are part of fixed-dose combinations like those with amlodipine. Wockhardt's presence in the telmisartan market is significant, particularly in regions like Asia-Pacific, where the market is expected to grow at a CAGR of 5.5% during the forecast period. The company's products are backed by robust R&D and manufacturing capabilities, contributing to the overall growth of the telmisartan market, which is projected to reach USD 4.26 billion by 2027. Wockhardt's commitment to quality and innovation makes it a key player in the global telmisartan market.

Hetero Drugs

Hetero Drugs is a notable producer of telmisartan, although it has faced challenges due to recalls related to nitrosamine impurities in its active pharmaceutical ingredients (APIs). Despite these issues, Hetero Labs has been a significant player in the global telmisartan market, which is projected to reach USD 5.41 billion by 2031, growing at a CAGR of 3.7% from 2024 to 2031. The company's manufacturing violations, however, led to FDA warnings and recalls, including the expansion of voluntary recalls for losartan potassium tablets due to unacceptable amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA). The global telmisartan market is driven by the rising prevalence of hypertension, affecting over 1.13 billion people globally, with telmisartan being a well-established antihypertensive therapy. Hetero's recalls have impacted its market standing, but the company remains a key player in the ARB market. For more information on the recalls, please visit the FDA updates and press announcements.